Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: Pechala's Reports
$25.00
Provider: Pechala's Reports
$15.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genetic Technologies Ltd Announces Independent Clinical Validation Study In Support Of The Utilization Of BREVAGen


Monday, 24 Jun 2013 05:15am EDT 

Genetic Technologies Ltd announced the publication online in Breast Cancer Research & Treatment on June 21, 2013 of a study titled, Using SNP genotypes to improve the discrimination of a simple breast cancer risk prediction model. These seven SNPs are utilized in the Company's BREVAGen breast cancer risk assessment test, and had previously been studied by Mealiffe et al. (J Natl Cancer Inst 102 (21):1618-1627) for an older cohort of cases and controls from the Women's Health Initiative clinical trial in the USA. The new Australian study supports the previous observation of Mealiffe et al. that including information on seven SNPs associated with breast cancer risk improves the discriminatory accuracy of BCRAT, and extends that observation in pre-menopausal women aged 35 to 49 years. 

Company Quote

0.033
-0.0010 -2.94%
23 Jul 2014